Home Newsfeeds Logitech Reaffirms Its FY23 Outlook

Logitech Reaffirms Its FY23 Outlook

Outlook Logitech reaffirmed its Fiscal Year 2023 outlook of between negative 8 percent and negative 4 percent sales growth in constant currency, and between $650

byBenzinga Newsdesk

October 25, 2022

1 minute read

Outlook

Logitech reaffirmed its Fiscal Year 2023 outlook of between negative 8 percent and negative 4 percent sales growth in constant currency, and between $650 million and $750 million in non-GAAP operating income.

FibroGen’s One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal

By Vandana Singh

June 7, 9:47 AM

FibroGen Inc (NASDAQ: FGEN) announced topline data from the Phase 3 LELANTOS-1 trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne Muscular Dystrophy (DMD)

FGEN

News

Gilead And Arcus Announced Anti-TIGIT Domvanalimab Continues To Demonstrate Consistent Improvement In Progression-Free Survival In Non-Small Cell Lung Cancer Study

By Charles Gross

June 3, 2:32 PM

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer

GILD

M&A
News

eBay Acquires the myFitment Group of Companies to Enhance Part and Accessories Listing Experience, Terms Not Disclosed

By Michael Horton

August 23, 4:01 PM

eBay Inc. (NASDAQ:EBAY), a global commerce leader that connects millions of sellers and buyers around the world, and the myFitment group of companies ("myFitment"), a leader in delivering the tools and support

EBAY

PhenixFIN Reports FY23 NAV Per Share Grew 23%, From $57.29 Per Share To $70.75 Per Share; Q4 Total Investment Income Of $5.7M

By Benzinga Newsdesk

December 22, 5:03 PM

PhenixFIN Corporation (NASDAQ:PFX, PFXNZ)))) (the "Company"), a publicly traded business development company, today announced its financial results for the fiscal fourth quarter of 2023. Highlights

PFX

Logitech Reaffirms Its FY23 Outlook

Related Posts

FibroGen’s One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal

Gilead And Arcus Announced Anti-TIGIT Domvanalimab Continues To Demonstrate Consistent Improvement In Progression-Free Survival In Non-Small Cell Lung Cancer Study

eBay Acquires the myFitment Group of Companies to Enhance Part and Accessories Listing Experience, Terms Not Disclosed

PhenixFIN Reports FY23 NAV Per Share Grew 23%, From $57.29 Per Share To $70.75 Per Share; Q4 Total Investment Income Of $5.7M